The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict

Biotech stocks saw some strength last week. Positive clinical readouts, a couple of M&A deals and hopes of drug companies clinching a broader opioid settlement agreement worked in favor of the sector.

Reata Pharmaceuticals Inc (NASDAQ: RETA) was among the strong performers of the week following a positive Phase 2 readout for its drug to treat Friedreich ataxia.

Here are the key catalysts for the upcoming week.